We are partnering with pharmaceutical and biotechnology companies to maximise the potential of the platform.

As a company we are flexible in our approach to collaboration. Our partnership models include:

Re-engineer We re-engineer our partner’s drug candidates to improve key properties.

Novel products We engineer known scaffolds to meet our partner’s product requirements.

Out-license We identify, launch and run internal drug development projects and out-license them to partners during pre-clinical development.

Tillotts Pharma AG X LabGenius


We are currently working with Tillotts Pharma AG to identify and develop new drug candidates for the treatment of inflammatory bowel disease (IBD). There is still a large unmet need for novel therapeutic approaches in IBD as many patients do not respond to the presently available drugs.

If you are interested in talking with us about licensing or a research collaboration, please contact us.